Form 4: Aerovate Therapeutics Officer Benjamin T. Dake Reports Stock Sale
SEC Form 4 Filing
Benjamin T. Dake, an officer at Aerovate Therapeutics, sold 3,432 shares of common stock on March 25, 2024, as part of a pre-arranged trading plan.
Summary
- On March 25, 2024, Benjamin T. Dake, President, Chief Operating Officer and Secretary of Aerovate Therapeutics, executed a transaction involving the company's common stock.
- Dake sold 3,432 shares at a weighted average price of $28.0068, with individual sales prices ranging from $27.95 to $28.385.
- The sale was conducted under a Rule 10b5-1 trading plan adopted on November 16, 2023.
- Additionally, Dake exercised a stock option to acquire 3,432 shares at a price of $10.61.
- Following these transactions, Dake directly owns 1,291 shares of common stock.
- Dake also holds options for 40,068 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing an insider stock transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for officers of publicly traded companies to have pre-arranged trading plans (Rule 10b5-1) to sell shares over time.
Stakeholder Impact
- The stock sale by an officer could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2021-12-14 | Date of grant for employee stock options for 58,000 shares. |
| 2022-01-14 | First installment of employee stock options vested. |
| 2023-11-16 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024-03-25 | Date of stock sale and option exercise. |
| 2031-12-13 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.